Navigation Links
New Research May Encourage Smokers to Jump-Start Their New Year's Resolution to Quit Smoking
Date:12/8/2008

PITTSBURGH, Dec. 8 /PRNewswire/ -- While New Year's is the most popular time to try quitting smoking, research shows the majority of smokers who try to quit at that time resume smoking in less than one week.(1) By starting a quit attempt early, smokers can avoid the pressures of a New Year's resolution and may be well on their way toward being smoke-free by January 1st. New research shows that smokers who use the 21 mg NicoDerm(R) CQ(R) nicotine patch every day for the first three weeks of a 10-week treatment significantly improve their chances of success.(2)

The study, published in the November issue of Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy, shows that people who use the 21 mg NicoDerm CQ nicotine patch every day for the first 21 days of quitting were three-times as likely of being smoke-free at the six week point in the course of treatment compared to those who do not wear their patch every day.(2) Further, when used as directed, the NicoDerm CQ patch can significantly increase a smoker's chance of quitting (versus placebo) and remaining smoke-free long-term (6 months or longer).(3)

"Quitting smoking can be one of the toughest New Year's resolutions to keep. The NicoDerm CQ nicotine patch is a hassle free approach to quitting smoking as smokers only need to apply it once-daily," said Saul Shiffman, Ph.D., lead researcher and professor in the departments of psychology and pharmaceutical science at the University of Pittsburgh. "While a smoker may slip and have a cigarette during the quitting process, by no means should they abandon quitting altogether. Smokers should keep wearing the NicoDerm CQ patch every day and it will keep working for you, even if you slip."

To help smokers get started on their pre-New Year's resolutions, NicoDerm CQ is offering a new bonus pack, which offers a free week of nicotine patches during a smoker's first step of therapy. For more information, smokers looking to quit can visit http://www.nicodermcq.com/21days.

Over-the-counter therapeutic nicotine products like the NicoDerm CQ patch, Nicorette gum and Commit lozenge are first-line treatments for smoking cessation and are thoroughly researched, well-understood and highly accessible stop smoking therapies.(4) GlaxoSmithKline Consumer Healthcare's therapeutic nicotine products are available without a doctor's prescription, in flexible dosing options at over 35,000 retail outlets across the country.(5) So a smoker who wants to quit doesn't have to wait to see a doctor to get help.

About NicoDerm CQ patch

NicoDerm CQ is the number one doctor-recommended patch to quit smoking. In fact, no treatment -- prescription or OTC -- is proven more effective than Nicoderm CQ in helping smokers quit long term.(5) NicoDerm CQ comes in three different strengths -- all specially formulated to control the release of nicotine for 24 hours. As cravings begin to diminish, this three-step process provides smokers with a lower dosage in each step, which allows a smoker to wean off nicotine gradually and safely. As with any treatment, failure to adhere to dosing instructions on the product label can limit effectiveness. When used as directed, NicoDerm CQ allows a smoker's body to gradually adjust to having less nicotine until eventually he doesn't need any at all. It also helps calm the cravings that make quitting smoking so hard by preventing cravings before they occur and providing more effective relief of cravings than willpower alone. Research has shown that using NicoDerm CQ to quit smoking significantly improves your chances of quitting successfully versus quitting cold turkey.(3)

About GlaxoSmithKline Consumer Healthcare

GlaxoSmithKline Consumer Healthcare is one of the world's largest over-the-counter consumer healthcare products companies. Its more than 30 well-known brands include the leading smoking cessation products, Nicorette(R) and NicoDerm(R)CQ(R), and Commit(R), as well as many medicine cabinet staples -- alli(R), Aquafresh(R), Sensodyne(R), and TUMS(R) -- which are trademarks owned by and/or licensed to GlaxoSmithKline Group of Companies.

About GlaxoSmithKline

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information visit: http://www.gsk.com.

    (1) Survey of 808 adult smokers interested in quitting conducted by
        GlaxoSmithKline Consumer Healthcare in October 2006.
    (2) Shiffman S, Sweeney CT, Ferguson S, et al. Adherence with Nicotine
        Patch Dosing and Treatment Efficacy: Secondary Analysis of a 10-Week
        Randomized, Double-Blind, Placebo-Controlled Clinical Trial of
        Over-the-Counter Patch in Adult Smokers.
    (3) Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine
        replacement therapy for smoking cessation. Cochrane Database of
        Systematic Reviews. 1996, Issue 3.
    (4) Fiore MC, Jaen CR, Baker TB, et al. Treating Tobacco Use and
        Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD:
        U.S. Department of Health and Human Services. Public Health Service.
        May 2008.
    (5) GSK Data on file.

     Contacts:          Mark Polisky, GolinHarris
                        312-729-4417
                        mpolisky@golinharris.com

                        Jennifer May, GlaxoSmithKline
                        Consumer Healthcare
                        412-200-3729
                        jennifer.l.may@gsk.com

'/>"/>
SOURCE GlaxoSmithKline Consumer Healthcare
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Research on the effects of stem cell source and patient age on transplantation outcomes
2. Research highlights new approaches to prevent blood clots
3. 50 years of hairy-cell leukemia research to be observed
4. Event Honoring Bill Gates Raises Over $1.5 Million for Sustainable Agriculture Research at The Hebrew University of Jerusalem
5. New Research Reports on Interventions that May Alter the Course of Epilepsy Diagnosis and Management
6. Researchers & Department of Defense Question Multiple Vaccine Administration
7. Researchers gain new insight on wonder of cell division
8. HALT-C researchers: Interferon as long-term treatment for hepatitis C not effective
9. Jefferson researcher awarded NIH grant
10. Researcher develops screening tool to identify patients with prediabetes
11. Partnership for Peak Healthcare Performance Research Shows Consumers Lack Involvement in Managing Their Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
(Date:6/23/2016)... MOUNTAIN VIEW, Calif. , June 23, 2016 ... 9:00 a.m. CST on Thursday, July 7, 2016 , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  ... Sciences, Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, ... The global pharmaceutical industry is witnessing ...
Breaking Medicine Technology: